Category: Accuray Inc.Syndicate content

Battle in Silicon Valley: Device makers trade barbs in the fight to gain share in robot assisted procedures

August 16, 2012 by Arezu Sarvestani

The best way to beat Intuitive Surgical out of the corner it has on the prostate cancer treatment market is by amping up the aggression, radiosurgery veteran and Varian chief medical officer John Adler tells

boxing gloves

Radiosurgery innovator and medtech veteran John Adler is ready for a fight.

The outspoken inventor of Accuray's (NSDQ:ARAY) CyberKnife system, as well as the company's founder and former CEO, Adler is an evangelist for radiosurgery and its potential in a variety of applications.

Study: Robot assisted prostate surgery may lower rates of incontinence, impotence

August 9, 2012 by MassDevice staff

Prostate surgery with robotic assistance may cause less impotence and incontinence than laparoscopic surgery, according to a small Italian study.

da Vinci robot assisted surgery

Robot assisted prostate surgery may lower rates of urinary incontinence and post-surgery impotence when compared with minimally invasive laparoscopy, according to a small Italian study.

The study only comprised 120 patients who were randomized to receive a prostatectomy with either an unnamed robot assistant or with tiny tools manipulated by hand. All surgeries were performed by a single surgeon.

Cyberknife: Man, that robot sure can dance

July 23, 2012 by MassDevice

See video

In this 2009 video from the American Society of Radiation Oncology annual meeting, employees from Sunnyvale, Calif.-based Accuray (NSDQ:ARAY) show off their dance moves.

Accuray nabs imaging systems maker Morphormics for $5.7M

July 16, 2012 by MassDevice staff

Radiosurgery devices company Accuray acquires medical imaging software systems maker Morphormics in a deal worth about $5.7 million.

Accuray logo

Accuray (NSDQ:ARAY) signed a definitive agreement to acquire medical imaging software systems maker Morphormics for $5.7 million, the company announced today.

Privately held Morphormics, founded by faculty of the University of North Carolina at Chapel Hill, develops software that recognizes and extracts anatomical structures from medical images.

U.S. orthopedics on the upswing, analysts say | Wall Street Beat

June 27, 2012 by MassDevice staff

A new survey of U.S. hip and knee surgeons adds to Wall Street analysts' confidence that the orthopedics market is looking up. Wall Street Beat

Wall Street analysts are predicting with increasing confidence that the U.S. orthopedics market is on the upswing following an industry survey suggesting a coming increase in procedure volumes.

A MEDACorp orthopedics survey of 65 U.S. hip and knee surgeons found improvements in 12-month procedure volume expectations and increased patient willingness for surgery, according to an investment note from Leerink Swann analyst Richard Newitter.

Abiomed slides on reimbursement risk rumors | Wall Street Beat

May 22, 2012 by MassDevice staff

Abiomed says it hasn't heard of any Medicare reimbursement concerns, but a note from a Wall Street analyst sends shares down 6%.; also, Accuray teams up with the German Cancer Research Center; AngioDynamics closes the $335M Navilyst merger; athenahealth may be eyeing Epocrates; Covidien launches offering to pay off senior notes; plus, a Funding Roundup and analysts' ups and downs. Wall Street Beat

Abiomed (NSDQ:ABMD) slid 6% in late afternoon trading following a note from a Wall Street analyst warning about Medicare reimbursement concerns for the company's star Impella heart pumps.

Accuray slides on lowered sales outlook | Earnings Roundup

May 9, 2012 by MassDevice staff

Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year; plus, Q1 sales, earnings up for Henry Schein; LeMaitre Vascular's Q1 profits soar; Mindray's Q1 profits slide despite double-digit sales boost; Stereotaxis boosts Q1 sales, slashes losses; Steris profits spike in 2011; Symmetry Medical's Q1 bottom line plunges; Syneron boosts Q1 sales, losses widen; and more. news

Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.

The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.